지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Objectives: This study was aimed to report a patient with metastatic pancreatic cancer treated with modified Bangam-tang and Gunchil-dan in conjunction with gemcitabine. There were better survival-related outcomes compared to gemcitabine alone. Methods: The patient with metastatic pancreatic cancer received gemcitabine as palliative chemotherapy since June 2016 concurrent with modified Bangam-tang and Gunchil-dan since October 2016 to October 2017. To evaluate the effect of treatment, tumor markers (carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA)), Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and overall survival were checked. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results: After 12 months with the combination treatment, levels of CA19-9 were decreased from 8747 to 265.7 ng/ml and CEA from 42.2 to 6.5 U/ml. Clinical partial response state was shown until May 2, 2017 and stable disease state was maintained from August 4, 2017. In March 2018, the patient got an operation including pancreatectomy and diagnosed with no evidence of disease state in September, 2018. In conclusion, it showed the overall survival of 29 months from June, 2016 to November, 2018. Serious adverse events were not identified. Conclusions: This study suggested that combined treatment with modified Bangam-tang and Gunchil-dan may show better outcome in patient with metastatic pancreatic cancer than gemcitabine alone.
목차
등록된 정보가 없습니다.
참고문헌 (18)
참고문헌 신청
The Korea Central Cancer Registry / 2018 / Annual report of cancer statistics in Korea in 2015
Ryan DP / 2014 / Pancreatic adenocarcinoma / N Engl J Med 371:1039~1049
Daniel D / 2013 / Increase survival in pancreatic cancer with nab-Paclitaxel plsu Gemcitabine / N Engl J Med 3:1691~1703
National Comprehensive Cancer Network / NCCN clinical practice guidelines in oncology: Pancreatic Adenocarcinoma. Version 1
Lee JJ / 2010 / A phase II study of an herbal decoction that includes Astragali Radix for cancer-associated anorexia in patient with advenced cancer / Integr Cancer Ther 9:24~31
Ryan DP / 2014 / Pancreatic adenocarcinoma / N Engl J Med 371:1039~1049
Daniel D / 2013 / Increase survival in pancreatic cancer with nab-Paclitaxel plsu Gemcitabine / N Engl J Med 3:1691~1703
National Comprehensive Cancer Network / NCCN clinical practice guidelines in oncology: Pancreatic Adenocarcinoma. Version 1
Lee JJ / 2010 / A phase II study of an herbal decoction that includes Astragali Radix for cancer-associated anorexia in patient with advenced cancer / Integr Cancer Ther 9:24~31
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Systemic Chemotherapy in Advanced Pancreatic Cancer
Gut and Liver
2016 .01
-
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
Cancer Research and Treatment
2021 .10
-
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
Cancer Research and Treatment
2017 .01
-
Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
Cancer Research and Treatment
2016 .01
-
항암화학요법과 통합의학치료를 병행하여 부분 관해 된 간전이 동반 말기 췌장암 1례
대한한방내과학회지
2020 .01
-
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
Investigative and Clinical Urology
2021 .11
-
Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
Yonsei Medical Journal
2021 .01
-
Establishment of a Pancreatic Cancer Stem Cell Model Using the SW1990 Human Pancreatic Cancer Cell Line in Nude Mice
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Cancer Research and Treatment
2015 .01
-
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
Gut and Liver
2021 .01
-
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
Cancer Research and Treatment
2015 .01
-
한방 단독치료로 전이 대장암의 반복적인 재발을 억제한 장기 생존 치험 1례
대한한방내과학회지
2019 .01
-
Ivermectin and gemcitabine combination treatment enhances antitumor effect in pancreatic cancer through mitochondria dysfunction
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer
Yonsei Medical Journal
2016 .01
-
A Case of Five-Year Survival in Metastatic Pancreatic Cancer
대한췌담도학회지
2024 .07
-
Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer
대한췌담도학회지
2020 .01
-
p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines
Cancer Research and Treatment
2015 .01
-
In vitro Study of the Antagonistic Effect of Low-dose Liquiritigenin on Gemcitabine-induced Capillary Leak Syndrome in Pancreatic Adenocarcinoma via Inhibiting ROS-Mediated Signalling Pathways
Asian Pacific journal of cancer prevention : APJCP
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0